Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tuan Dong Si
Institution:
Blueprint Medicines (United States)
Observed institution:
Blueprint Medicines (United States)
OpenAlex ID:
A5035673230
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
2020
·
Cissimol P. Joseph
, Sarah N. Abaricia
, et al.
·
The Oncologist
·
38
PDF
A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome
2022
·
Mariana Castells
, Tuan Dong Si
, et al.
·
Journal of Allergy and Clinical Immunology
·
8
PDF
Abstract CT122: Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers
2021
·
Nimita Dave
, Marissa Devlin
, et al.
·
Cancer Research
·
8
Show more works
View as search
Works count:
3
Citation count:
54
H-index:
3
I10-index:
1
Year
Topic
Type
